These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 25919121)

  • 1. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
    Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
    J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
    Brown JT; Bishop JR
    Pharmacogenomics; 2015; 16(13):1513-20. PubMed ID: 26314574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
    Michelson D; Read HA; Ruff DD; Witcher J; Zhang S; McCracken J
    J Am Acad Child Adolesc Psychiatry; 2007 Feb; 46(2):242-51. PubMed ID: 17242628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD.
    Trzepacz PT; Williams DW; Feldman PD; Wrishko RE; Witcher JW; Buitelaar JK
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):79-86. PubMed ID: 17698328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
    Brown JT; Bishop JR; Sangkuhl K; Nurmi EL; Mueller DJ; Dinh JC; Gaedigk A; Klein TE; Caudle KE; McCracken JT; de Leon J; Leeder JS
    Clin Pharmacol Ther; 2019 Jul; 106(1):94-102. PubMed ID: 30801677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.
    Brown JT; Abdel-Rahman SM; van Haandel L; Gaedigk A; Lin YS; Leeder JS
    Clin Pharmacol Ther; 2016 Jun; 99(6):642-50. PubMed ID: 26660002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.
    Guo HL; Wu DD; Fu D; Li Y; Wang J; Zhang YY; Wang WJ; Huang J; Fang WR; Xu J; Hu YH; Liu QQ; Chen F
    Transl Psychiatry; 2024 Mar; 14(1):151. PubMed ID: 38504095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
    Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E
    Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
    Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
    J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
    Yu G; Li GF; Markowitz JS
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):314-26. PubMed ID: 26859445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications.
    Brown JT
    Methods Mol Biol; 2022; 2547():427-436. PubMed ID: 36068472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of CYP2D6 genotype and response to tetrabenazine.
    Mehanna R; Hunter C; Davidson A; Jimenez-Shahed J; Jankovic J
    Mov Disord; 2013 Feb; 28(2):210-5. PubMed ID: 23280482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
    Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
    Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
    Camporeale A; Porsdal V; De Bruyckere K; Tanaka Y; Upadhyaya H; Deix C; Deberdt W
    J Psychopharmacol; 2015 Jan; 29(1):3-14. PubMed ID: 25424623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder.
    Upadhyaya H; Kratochvil C; Ghuman J; Camporeale A; Lipsius S; D'Souza D; Tanaka Y
    J Child Adolesc Psychopharmacol; 2015 Dec; 25(10):799-809. PubMed ID: 25265343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.
    ter Laak MA; Temmink AH; Koeken A; van 't Veer NE; van Hattum PR; Cobbaert CM
    Pediatr Neurol; 2010 Sep; 43(3):159-62. PubMed ID: 20691935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder:
    Fu D; Guo HL; Hu YH; Chen F
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):98-103. PubMed ID: 36655671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of atomoxetine.
    Sauer JM; Ring BJ; Witcher JW
    Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.